Helmerich & Payne (HP) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
1 Dec, 2025Executive summary
Annual meeting scheduled for March 5, 2025, will be held virtually for shareholder participation.
Shareholders are encouraged to review proxy materials online or request copies before voting.
Voting matters and shareholder proposals
Shareholders will vote on the election of ten directors to the board.
Advisory vote on executive compensation is included on the agenda.
Ratification of Ernst & Young LLP as independent auditors for 2025 is up for approval.
Other business may be addressed as appropriate during the meeting.
Board of directors and corporate governance
Nominees for director include Delaney M. Bellinger, Belgacem Chariag, Kevin G. Cramton, Randy A. Foutch, Hans Helmerich, Elizabeth R. Killinger, John W. Lindsay, José R. Mas, Donald F. Robillard, Jr., and John D. Zeglis.
Latest events from Helmerich & Payne
- All board proposals passed with strong support, marking a smooth CEO transition.HP
AGM 20264 Mar 2026 - $230M EBITDA, $1B+ revenue, $97M net loss, $260M debt repaid, strong global growth.HP
Q1 20265 Feb 2026 - $1.97B KCA Deutag deal creates a global leader, boosts cash flow, and expands international scale.HP
Q3 20243 Feb 2026 - Virtual annual meeting to vote on directors, auditor, compensation, and incentive plan.HP
Proxy Filing22 Jan 2026 - Shareholders to vote on board, auditor, executive pay, and expanded incentive plan amid strong results.HP
Proxy Filing22 Jan 2026 - Strong FY24, global expansion via KCA Deutag, and lower 2025 CapEx to drive cash flow.HP
Q4 202414 Jan 2026 - KCA Deutag acquisition expands global scale as Q1 profit drops on higher costs.HP
Q1 202517 Dec 2025 - 2024 saw robust results, global growth, and strong governance, with all board proposals recommended.HP
Proxy Filing1 Dec 2025 - Q3 saw $1.04B revenue, $268M EBITDA, goodwill impairment, and strong KCAD integration.HP
Q3 202523 Nov 2025